表紙
市場調查報告書

雙特異性抗體的癌症治療藥的全球市場:2019年∼2023年

Global Bispecific Antibodies for Cancer Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 827312
出版日期 內容資訊 英文 117 Pages
訂單完成後即時交付
價格
雙特異性抗體的癌症治療藥的全球市場:2019年∼2023年 Global Bispecific Antibodies for Cancer Market 2019-2023
出版日期: 2019年04月17日內容資訊: 英文 117 Pages
簡介

雙特異性抗體可以同時處理兩種不同的抗原,這些抗原足以靶向癌症發病機理中涉及的兩種途徑,這個優於單克隆抗體療法的優勢預計今後將推動市場急速成長。預計從2019年到2023年這個本報告的市場預測期間,雙特異性抗體的癌症治療藥全球市場將以超越30%的年複合成長率 (CAGR) 持續擴大。

本報告涵括雙特異性抗體的癌症治療藥的全球市場,透過對市場成長促進因素和市場課題,市場趨勢,以及市場競爭情形的詳細調查,來進行市場現狀分析以及未來預測。

第1章 摘要整理

第2章 本報告涵蓋範圍

  • 序言
  • 對美金的匯率

第3章 市場概況

  • 市場生態系統
  • 市場特徵
  • 市場分類分析

第4章 市場規模

  • 市場定義
  • 市場規模估計
  • 現行市場規模及未來市場規模預測

第5章 波特的五力分析

  • 買方議價能力
  • 賣主談判力
  • 新加入企業帶來的威脅
  • 替代品帶來的威脅
  • 企業間的競爭關係
  • 市場情形

第6章 客戶情形

第7章 標的別市場分類

  • 標的別市場分類
  • 標的別比較
  • CD19/CD3 - 市場規模及未來預測
  • CD30/CD16A - 市場規模及未來預測
  • 標的別市場機會

第8章 地區市場情形

  • 地區市場分類
  • 地區市場比較
  • 北美 - 市場規模及未來預測
  • 歐洲 - 市場規模及未來預測
  • 亞洲 - 市場規模及未來預測
  • 其他地區 - 市場規模及未來預測
  • 主要國家
  • 市場機會

第9章 決策要素架構

第10章 市場成長推動因素與課題

  • 市場成長促進因素
  • 市場課題

第11章 市場趨勢

第12章 業者情勢

  • 概要
  • 形勢的快速發展

第13章 主要供應商分析

  • 調查交易廠商
  • 供應商類別
  • 各供應商的市場定位
  • Amgen Inc.
  • Astellas Pharma Inc.株式會社
  • Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd.
  • Merus
  • Regeneron Pharmaceuticals, Inc.AN INTERNATIONAL

第14章 附錄

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31178

About this market

The advantages of bispecific antibodies over monoclonal antibodies is one of the key factors expected to propel the market growth during the forecast period. The limitations of monoclonal antibodies such as limited binding abilities for specific antigens have encouraged researchers to improve and increase the efficacy of the molecules and enhance their function by developing antibodies with two or more targets. Bispecific antibodies can simultaneously address two different antigens, which are sufficient to target two trails involved in cancer pathogenesis, and therefore, provide advantages over monoclonal antibodies therapy. Hence, the advantages of bispecific antibodies will drive the growth of the market in the upcoming years. Technavio's analysts have predicted that the bispecific antibodies for cancer market will register a CAGR of over 30% by 2023.

Market Overview

Increasing prevalence of cancer

The increase in the prevalence of cancer across the world will fuel the demand for bispecific antibodies to treat these cancers, thereby driving the growth of the market.

The high cost of drug

Most of the cancer patients in low- and middle-income countries fail to complete the course of drug therapy as these drugs are priced beyond their reach.

For the detailed list of factors that will drive and challenge the growth of the bispecific antibodies for cancer market during 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented with the presence of several market players. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: CUSTOMER LANDSCAPE

PART 07: MARKET SEGMENTATION BY TARGET

  • Market segmentation by target
  • Comparison by target
  • CD19/CD3 - Market size and forecast 2018-2023
  • CD30/CD16A - Market size and forecast 2018-2023
  • Market opportunity by target

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Market trends

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen Inc.
  • Astella Pharma Inc.
  • Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd.
  • Merus
  • Regeneron Pharmaceuticals, Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global oncology therapeutics market
  • Exhibit 02: Segments of global oncology therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Bispecific antibodies for cancer under development
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Customer landscape
  • Exhibit 19: Target - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by target
  • Exhibit 21: CD19/CD3 - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: CD19/CD3 - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: CD30/CD16A - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: CD30/CD16A - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by target
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Key leading countries
  • Exhibit 37: Market opportunity
  • Exhibit 38: Impact of drivers and challenges
  • Exhibit 39: Pipeline for bispecific antibodies for cancer treatment
  • Exhibit 40: Vendor landscape
  • Exhibit 41: Landscape disruption
  • Exhibit 42: Vendors covered
  • Exhibit 43: Vendor classification
  • Exhibit 44: Market positioning of vendors
  • Exhibit 45: Amgen Inc. - Vendor overview
  • Exhibit 46: Amgen Inc. - Product segments
  • Exhibit 47: Amgen Inc. - Organizational developments
  • Exhibit 48: Amgen Inc. - Geographic focus
  • Exhibit 49: Amgen Inc. - Key offerings
  • Exhibit 50: Astella Pharma Inc. - Vendor overview
  • Exhibit 51: Astella Pharma Inc. - Business segments
  • Exhibit 52: Astella Pharma Inc. - Organizational developments
  • Exhibit 53: Astella Pharma Inc. - Key offerings
  • Exhibit 54: Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd. - Vendor overview
  • Exhibit 55: Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd. - Key offerings
  • Exhibit 56: Merus - Vendor overview
  • Exhibit 57: Merus - Product segments
  • Exhibit 58: Merus - Key offerings
  • Exhibit 59: Regeneron Pharmaceuticals, Inc. - Vendor overview
  • Exhibit 60: Regeneron Pharmaceuticals, Inc. - Business segments
  • Exhibit 61: Regeneron Pharmaceuticals, Inc. - Organizational developments
  • Exhibit 62: Regeneron Pharmaceuticals, Inc. - Key offerings
  • Exhibit 63: Validation techniques employed for market sizing